Fuchs, Eberhard

[["dc.bibliographiccitation.firstpage","31"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Cell and Tissue Research"],["dc.bibliographiccitation.lastpage","41"],["dc.bibliographiccitation.volume","357"],["dc.contributor.author","Fluegge, Gabriele"],["dc.contributor.author","Araya-Callis, Carolina"],["dc.contributor.author","Garea-Rodriguez, Enrique"],["dc.contributor.author","Stadelmann-Nessler, Christine"],["dc.contributor.author","Fuchs, Eberhard"],["dc.date.accessioned","2018-11-07T09:38:14Z"],["dc.date.available","2018-11-07T09:38:14Z"],["dc.date.issued","2014"],["dc.description.abstract","The protein NDRG2 (N-myc downregulated gene 2) is expressed in astrocytes. We show here that NDRG2 is located in the cytosol of protoplasmic and fibrous astrocytes throughout the mammalian brain, including Bergmann glia as observed in mouse, rat, tree shrew, marmoset and human. NDRG2 immunoreactivity is detectable in the astrocytic cell bodies and excrescencies including fine distal processes. Glutamatergic and GABAergic nerve terminals are associated with NDRG2 immunopositive astrocytic processes. Muller glia in the retina displays no NDRG2 immunoreactivity. NDRG2 positive astrocytes are more abundant and more evenly distributed in the brain than GFAP (glial fibrillary acidic protein) immunoreactive cells. Some regions with very little GFAP such as the caudate nucleus show pronounced NDRG2 immunoreactivity. In white matter areas, NDRG2 is less strong than GFAP labeling. Most NDRG2 positive somata are immunoreactive for S100 but not all S100 cells express NDRG2. NDRG2 positive astrocytes do not express nestin and NG2 (chondroitin sulfate proteoglycan 4). The localization of NDRG2 overlaps only partially with that of aquaporin 4, the membrane-bound water channel that is concentrated in the astrocytic endfeet. Reactive astrocytes at a cortical lesion display very little NDRG2, which indicates that expression of the protein is reduced in reactive astrocytes. In conclusion, our data show that NDRG2 is a specific marker for a large population of mature, non-reactive brain astrocytes. Visualization of NDRG2 immunoreactive structures may serve as a reliable tool for quantitative studies on numbers of astrocytes in distinct brain regions and for high-resolution microscopy studies on distal astrocytic processes."],["dc.identifier.doi","10.1007/s00441-014-1837-5"],["dc.identifier.isi","000338759900003"],["dc.identifier.pmid","24816982"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/10233"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/33027"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","1432-0878"],["dc.relation.issn","0302-766X"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","NDRG2 as a marker protein for brain astrocytes"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","452"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Brain Pathology"],["dc.bibliographiccitation.lastpage","464"],["dc.bibliographiccitation.volume","26"],["dc.contributor.author","Stassart, Ruth Martha"],["dc.contributor.author","Helms, Gunther"],["dc.contributor.author","Garea-Rodriguez, Enrique"],["dc.contributor.author","Nessler, Stefan"],["dc.contributor.author","Hayardeny, Liat"],["dc.contributor.author","Wegner, Christiane"],["dc.contributor.author","Schlumbohm, Christina"],["dc.contributor.author","Fuchs, Eberhard"],["dc.contributor.author","Brueck, Wolfgang"],["dc.date.accessioned","2018-11-07T10:12:06Z"],["dc.date.available","2018-11-07T10:12:06Z"],["dc.date.issued","2016"],["dc.description.abstract","Multiple sclerosis (MS) is the most common cause for sustained disability in young adults, yet treatment options remain very limited. Although numerous therapeutic approaches have been effective in rodent models of experimental autoimmune encephalomyelitis (EAE), only few proved to be beneficial in patients with MS. Hence, there is a strong need for more predictive animal models. Within the past decade, EAE in the common marmoset evolved as a potent, alternative model for MS, with immunological and pathological features resembling more closely the human disease. However, an often very rapid and severe disease course hampers its implementation for systematic testing of new treatment strategies. We here developed a new focal model of EAE in the common marmoset, induced by myelin oligodendrocyte glycoprotein (MOG) immunization and stereotactic injections of proinflammatory cytokines. At the injection site of cytokines, confluent inflammatory demyelinating lesions developed that strongly resembled human MS lesions. In a proof-of-principle treatment study with the immunomodulatory compound laquinimod, we demonstrate that targeted EAE in marmosets provides a promising and valid tool for preclinical experimental treatment trials in MS research."],["dc.identifier.doi","10.1111/bpa.12292"],["dc.identifier.isi","000380034000002"],["dc.identifier.pmid","26207848"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/40173"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.relation.issn","1750-3639"],["dc.relation.issn","1015-6305"],["dc.title","A New Targeted Model of Experimental Autoimmune Encephalomyelitis in the Common Marmoset"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","290"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Journal of Medical Primatology"],["dc.bibliographiccitation.lastpage","296"],["dc.bibliographiccitation.volume","45"],["dc.contributor.author","Helms, Gunther"],["dc.contributor.author","Schlumbohm, Christina"],["dc.contributor.author","Garea-Rodriguez, Enrique"],["dc.contributor.author","Dechent, Peter"],["dc.contributor.author","Fuchs, Eberhard"],["dc.date.accessioned","2018-11-07T10:05:33Z"],["dc.date.available","2018-11-07T10:05:33Z"],["dc.date.issued","2016"],["dc.description.abstract","BackgroundThis study determined the pharmacokinetics of the contrast agent gadobutrol in marmosets by quantitative MRI to derive guidelines for neuroimaging protocols. MethodsLocal concentrations of gadobutrol were determined from consecutive gradient echo-based mapping of the relaxation rate R1 on a clinical 3T MRI scanner. Half-time of renal elimination was measured after injection of a triple dose of gadobutrol (0.3mmol/kg) into the saphenous vein. A first-order single-compartment model was fitted to the measured R1 values and verified by blood analysis. ResultsSlow injection (1.5minutes) resulted in an elimination half-time of 264minutes. After bolus injection (15seconds), elimination was much slower (62 +/- 8minutes) with 45% larger distribution volumes. Importantly, more gadobutrol entered the cerebrospinal fluid. ConclusionsSlow injection and a latency of about 20minutes are recommended to avoid extravasation. Application of a triple dose of gadobutrol compensates for the fast elimination in healthy marmosets."],["dc.description.sponsorship","Schilling Foundation; EU ERA-Net NEURON (PARKCDNF)"],["dc.identifier.doi","10.1111/jmp.12227"],["dc.identifier.isi","000387363700002"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/38917"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.relation.issn","1600-0684"],["dc.relation.issn","0047-2565"],["dc.title","Pharmacokinetics of the MRI contrast agent gadobutrol in common marmoset monkeys (Callithrix jacchus)"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Journal of Neuroscience Methods"],["dc.bibliographiccitation.volume","222"],["dc.contributor.author","Garea-Rodriguez, Enrique"],["dc.contributor.author","Schlumbohm, Christina"],["dc.contributor.author","Czeh, Boldizsar"],["dc.contributor.author","Koenig, Jessica"],["dc.contributor.author","Helms, Gunther"],["dc.contributor.author","Heckmann, Cornelia"],["dc.contributor.author","Meller, Birgit"],["dc.contributor.author","Meller, Johannes"],["dc.contributor.author","Fuchs, Eberhard"],["dc.date.accessioned","2018-11-07T09:44:54Z"],["dc.date.available","2018-11-07T09:44:54Z"],["dc.date.issued","2014"],["dc.format.extent","260"],["dc.identifier.doi","10.1016/j.jneumeth.2013.10.023"],["dc.identifier.isi","000331672000031"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/34496"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Bv"],["dc.relation.issn","1872-678X"],["dc.relation.issn","0165-0270"],["dc.title","Visualizing dopamine transporter integrity with iodine-123-FP-CIT SPECT in combination with high resolution MRI in the brain of the common marmoset monkey (vol 210, pg 195, 2013)"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","121"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Journal of Neuroscience Methods"],["dc.bibliographiccitation.lastpage","131"],["dc.bibliographiccitation.volume","215"],["dc.contributor.author","Helms, Gunther"],["dc.contributor.author","Garea-Rodriguez, Enrique"],["dc.contributor.author","Schlumbohm, Christina"],["dc.contributor.author","König, Jessica"],["dc.contributor.author","Dechent, Peter"],["dc.contributor.author","Fuchs, Eberhard"],["dc.contributor.author","Wilke, Melanie"],["dc.date.accessioned","2017-09-07T11:43:43Z"],["dc.date.available","2017-09-07T11:43:43Z"],["dc.date.issued","2013"],["dc.description.abstract","Purpose was to adapt structural and quantitative magnetic resonance imaging (MRI) from humans to common marmoset monkeys on a clinical 3T scanner and to demonstrate the value for translational research.Three-dimensional T1- and T2-weighted MRI and gradient echo-based multi-parameter mapping was performed on nine adult animals using a wrist coil. Structural MRI was applied in a model of targeted experimental autoimmune encephalomyelitis (EAE). Magnetization transfer (MT) and T1 parameter maps were used to depict axon-rich cortical areas. After intraveneous triple dose of gadobutrol, the excretion half-time was determined from consecutive measurements of R1 = 1/T1. Diffusion tensor imaging (DTI) was performed at 1 mm resolution.At 0.4 mm resolution, total measurement time (30 min) was compatible with injection anesthesia, permitting rapid screening and frequent follow-up. Structural MRI depicted the EAE lesion in white matter. Quantitative values of T1, MT, and R2 in marmoset brain were comparable to humans, except for smaller R2 indicating lower iron content in basal ganglia. The middle temporal V5 area and the cortical layer IV could be identified, but were considerably better delineated when averaging two images at 0.33 mm resolution (70 min). A similar distribution volume (23%), but a shorter excretion half time than in humans (30 min) was observed. DTI was feasible only in larger structures, such as major axonal tracts.High-resolution MRI of common marmosets proved feasible using clinical MRI hardware. A rapid 3D examination protocol was established for screening under injection anesthesia, thus avoiding the adverse effects of inhalation anesthesia."],["dc.identifier.doi","10.1016/j.jneumeth.2013.02.011"],["dc.identifier.gro","3151620"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/8433"],["dc.language.iso","en"],["dc.notes.status","public"],["dc.notes.submitter","chake"],["dc.relation.issn","0165-0270"],["dc.title","Structural and quantitative neuroimaging of the common marmoset monkey using a clinical MRI system"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dc.type.peerReviewed","no"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","Multiple Sclerosis Journal"],["dc.bibliographiccitation.volume","19"],["dc.contributor.author","Brueck, Wolfgang"],["dc.contributor.author","Garea-Rodriguez, Enrique"],["dc.contributor.author","Hayardeny, Liat"],["dc.contributor.author","Wegner, C."],["dc.contributor.author","Stassart, Ruth Martha"],["dc.contributor.author","Schlumbohm, Christina"],["dc.contributor.author","Fuchs, E."],["dc.date.accessioned","2018-11-07T09:18:50Z"],["dc.date.available","2018-11-07T09:18:50Z"],["dc.date.issued","2013"],["dc.format.extent","139"],["dc.identifier.isi","000328751401132"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/28493"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Sage Publications Ltd"],["dc.publisher.place","London"],["dc.relation.conference","29th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis / 18th Annual Conference of Rehabilitation in MS"],["dc.relation.eventlocation","Copenhagen, DENMARK"],["dc.relation.issn","1477-0970"],["dc.relation.issn","1352-4585"],["dc.title","A new, targetted animal model of multiple sclerosis in the common marmoset"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","e0149776"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","PLoS ONE"],["dc.bibliographiccitation.volume","11"],["dc.contributor.author","Garea-Rodriguez, Enrique"],["dc.contributor.author","Eesmaa, Ave"],["dc.contributor.author","Lindholm, Paeivi"],["dc.contributor.author","Schlumbohm, Christina"],["dc.contributor.author","Koenig, Jessica"],["dc.contributor.author","Meller, Birgit"],["dc.contributor.author","Krieglstein, Kerstin"],["dc.contributor.author","Helms, Gunther"],["dc.contributor.author","Saarma, Mart"],["dc.contributor.author","Fuchs, Eberhard"],["dc.date.accessioned","2018-11-07T10:18:05Z"],["dc.date.available","2018-11-07T10:18:05Z"],["dc.date.issued","2016"],["dc.description.abstract","Cerebral dopamine neurotrophic factor (CDNF) belongs to a newly discovered family of evolutionarily conserved neurotrophic factors. We demonstrate for the first time a therapeutic effect of CDNF in a unilateral 6-hydroxydopamine (6-OHDA) lesion model of Parkinson's disease in marmoset monkeys. Furthermore, we tested the impact of high chronic doses of human recombinant CDNF on unlesionedmonkeys and analyzed the amino acid sequence ofmarmoset CDNF. The severity of 6-OHDA lesions and treatment effects weremonitored in vivo using 123I-FP-CIT (DaTSCAN) SPECT. Quantitative analysis of 123I-FP-CIT SPECT showed a significant increase of dopamine transporter binding activity in lesioned animals treated with CDNF. Glial cell line-derived neurotrophic factor (GDNF), a well-characterized and potent neurotrophic factor for dopamine neurons, served as a control in a parallel comparison with CDNF. By contrast with CDNF, only single animals responded to the treatment with GDNF, but no statistical difference was observed in the GDNF group. However, increased numbers of tyrosine hydroxylase immunoreactive neurons, observed within the lesioned caudate nucleus of GDNF-treated animals, indicate a strong bioactive potential of GDNF."],["dc.identifier.doi","10.1371/journal.pone.0149776"],["dc.identifier.isi","000371276100150"],["dc.identifier.pmid","26901822"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/12929"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/41359"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Public Library Science"],["dc.relation.issn","1932-6203"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Comparative Analysis of the Effects of Neurotrophic Factors CDNF and GDNF in a Nonhuman Primate Model of Parkinson's Disease"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","195"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Journal of Neuroscience Methods"],["dc.bibliographiccitation.lastpage","201"],["dc.bibliographiccitation.volume","210"],["dc.contributor.author","Garea-Rodriguez, Enrique"],["dc.contributor.author","Schlumbohm, Christina"],["dc.contributor.author","Czeh, Boldizsar"],["dc.contributor.author","Koenig, Jessica"],["dc.contributor.author","Helms, Gunther"],["dc.contributor.author","Heckmann, Cornelia"],["dc.contributor.author","Meller, Birgit"],["dc.contributor.author","Meller, Johannes"],["dc.contributor.author","Fuchs, Eberhard"],["dc.date.accessioned","2018-11-07T09:05:41Z"],["dc.date.available","2018-11-07T09:05:41Z"],["dc.date.issued","2012"],["dc.description.abstract","Considerable progress has been made in small animal single photon emission computed tomography (SPECT) imaging in the field of Parkinson's disease. In preclinical research, there is an increasing demand for in vivo imaging techniques to apply to animal models. Here, we report the first protocol for dopamine transporter (DAT) SPECT in common marmosets using the radioligand I-123-N-omega-fluoropropyl-2 beta-carbomethoxy-3 beta-{4-iodophenyl}nortropane (I-123-FP-CIT). Serial SPECT images were obtained on an upgraded clinical scanner to determine the distribution kinetics of I-123-FP-CIT in the marmoset brain. After intravenous injection of approximately 60 MBq of the radiotracer I-123-FP-CIT, stable and specific striatal uptake was observed for at least 4 h. Analysis of plasma samples showed rapid disappearance of the radiotracer from blood plasma within a few minutes after application, with activity declining to 4.1% of the administered activity. Structural magnetic resonance imaging (MRI) at 400 mu m resolution provided the details of the underlying anatomy. In a marmoset model of Parkinson's disease, which was generated by unilateral injections of 6-hydroxydopamine (6-OHDA) into the nigro-striatal projection pathway, complete loss of striatal DAT binding in combination with behavioral deficits was observed. The presented study demonstrates that I-123-FP-CIT SPECT is a suitable tool to investigate DAT integrity in preclinical studies on common marmosets. (C) 2012 Elsevier B.V. All rights reserved."],["dc.identifier.doi","10.1016/j.jneumeth.2012.07.009"],["dc.identifier.isi","000309376900009"],["dc.identifier.pmid","22827895"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/11318"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/25384"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Bv"],["dc.relation.issn","0165-0270"],["dc.rights","CC BY-NC-ND 3.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc-nd/3.0"],["dc.title","Visualizing dopamine transporter integrity with iodine-123-FP-CIT SPECT in combination with high resolution MRI in the brain of the common marmoset monkey"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]